Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026 ...

As previously announced, OXB will report its preliminary results for the twelve months ended 31 December 2025 on 26 March ...

Live webcasts and recordings of presentations, where available, will be accessible under ‘Results, Reports, Presentations & Webcasts’ in the Investor Relations section of OXB’s website at www.oxb.com.

Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...

Investors attending any of the above conferences who would like to meet with OXB are welcome to contact the Company’s IR team via [email protected]. Live webcasts and recordings of presentations, where ...

OXB announces date for Capital Markets Day and participation in upcoming investor conferences Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, ...